Nanobiotix Shares Fall 13% in a Week After a 734% Rally Over a Year
Nanobiotix falls 2.47% mid-morning on Thursday, at 25.24 euros, in a declining Paris market. The stock, which has increased its value by more than eightfold in a year, records its fourth consecutive session of decline, bringing the weekly correction to nearly 13%.
Rapid Correction Phase After Remarkable Rally
Following a spectacular 45% rally over three months and an annual performance of 734%, Nanobiotix is undergoing a rapid correction phase. The current price of 25.24 euros is now at the lower end of the Bollinger Bands (lower boundary at 23.85 euros), signaling a potential oversold zone. The stock has approached its 50-day moving average, established at 24.22 euros, a level that could act as a technical stabilization point after the recent surge. The RSI stands at 49, in a neutral zone, indicating that the selling pressure has not yet pushed the stock into confirmed oversold territory. The nearest support threshold is at 21.65 euros, while resistance is identified at 33.50 euros. The price thus moves within a broad corridor, reflecting a high monthly volatility of 23.45%.
Market Downturn Amidst Tense Trading Environment
Nanobiotix's decline this morning occurs in a tense market environment. The CAC 40 is down 0.72% during the session, at 8,204.70 points, while the SBF 120 loses 0.68%. The healthcare sector shows mixed dynamics: Sanofi is slightly up by 0.36%, while UCB is down by 0.97%. The negative beta of Nanobiotix (-0.68) illustrates a behavior decoupled from major indices, making comparisons with the overall market less relevant for explaining the stock movements. This coefficient reflects the unique profile of the French biotech, whose variations depend more on specific catalysts than on the macroeconomic context. The ongoing correction brings the stock back to levels not seen since mid-March, erasing in a few sessions part of the gains accumulated since the beginning of the year.
